Pulmonary Hypertension disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PLM037 MIFTS: 77	Pulmonary Hypertension Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Pulmonary Hypertension

MalaCards integrated aliases for Pulmonary Hypertension:

Name: Pulmonary Hypertension ⁴¹ ³⁸ ¹² ⁷⁶ ⁴³ ³ ¹⁵ ⁶³ ⁷³

Primary Pulmonary Hypertension ⁴¹ ¹² ⁷⁶ ³⁷ ²⁹ ⁵⁵ ⁶ ¹⁵

Idiopathic Pulmonary Arterial Hypertension ⁷³

Idiopathic Pulmonary Hypertension ⁷³

Hypertension, Pulmonary ⁴⁴

Hypertension Pulmonary ⁵⁵

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the circulatory system

Pulmonary heart disease and diseases of pulmonary circulation

Other pulmonary heart diseases

Primary pulmonary hypertension

External Ids:

Disease Ontology ¹² DOID:14557 DOID:6432

ICD10 ³³ I27.0 I27.20

ICD9CM ³⁵ 416.0

NCIt ⁵⁰ C97119 C3120

SNOMED-CT ⁶⁸ 26174007 70995007

MeSH ⁴⁴ D006976

KEGG ³⁷ H01619

UMLS ⁷³ C0152171 C0020542 C3203102

Sources

Summaries for Pulmonary Hypertension

MedlinePlus : ⁴³ Pulmonary hypertension (PH) is high blood pressure in the arteries to your lungs. It is a serious condition. If you have it, the blood vessels that carry blood from your heart to your lungs become hard and narrow. Your heart has to work harder to pump the blood through. Over time, your heart weakens and cannot do its job and you can develop heart failure. Symptoms of PH include Shortness of breath during routine activity, such as climbing two flights of stairs Tiredness Chest pain A racing heartbeat Pain on the upper right side of the abdomen Decreased appetite As PH worsens, you may find it hard to do any physical activities. There are two main kinds of PH. One runs in families or appears for no known reason. The other kind is related to another condition, usually heart or lung disease. There is no cure for PH. Treatments can control symptoms. They involve treating the heart or lung disease, medicines, oxygen, and sometimes lung transplantation. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Hypertension, also known as primary pulmonary hypertension, is related to pulmonary hypertension, primary, 1 and chronic thromboembolic pulmonary hypertension, and has symptoms including dyspnea, angina pectoris and edema. An important gene associated with Pulmonary Hypertension is MIR759 (MicroRNA 759), and among its related pathways/superpathways are TGF-beta signaling pathway and MicroRNAs in cancer. The drugs Adcirca and Adempas have been mentioned in the context of this disorder. Affiliated tissues include Lung, heart and lung, and related phenotypes are cardiovascular system and muscle

Disease Ontology : ¹² A hypertension characterized by an increase of blood pressure in the pulmonary artery, pulmonary vein or pulmonary capillaries.

CDC : ³ Pulmonary hypertension occurs when the pressure in the blood vessels leading from the heart to the lungs is too high. The heart pumps blood from the right ventricle to the lungs to get oxygen. Because the blood does not have to travel very far, the pressure in this side of the heart and in the artery taking blood from the right ventricle to the lungs is normally low—normally much lower than systolic or diastolic blood pressure. When the pressure in this artery gets too high, the arteries in the lungs can narrow and then the blood does not flow as well as it should resulting in less oxygen in the blood.1

PubMed Health : ⁶³ About pulmonary hypertension: Pulmonary hypertension (PULL-mun-ary HI-per-TEN-shun), or PH, is increased pressure in the pulmonary arteries. These arteries carry blood from your heart to your lungs to pick up oxygen.PH causes symptoms such as shortness of breath during routine activity (for example, climbing two flights of stairs), tiredness, chest pain, and a racing heartbeat. As the condition worsens, its symptoms may limit all physical activity.

Wikipedia : ⁷⁶ Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of... more...

Sources

Related Diseases for Pulmonary Hypertension

Diseases in the Pulmonary Hypertension family:

Pulmonary Hypertension, Primary, 1	Pulmonary Hypertension, Primary, Autosomal Recessive
Pulmonary Hypertension, Primary, 2	Pulmonary Hypertension, Primary, 3
Pulmonary Hypertension, Primary, 4

Diseases related to Pulmonary Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 564)

#	Related Disease	Score	Top Affiliating Genes
1	pulmonary hypertension, primary, 1	34.5	ACVRL1 BMPR2 EDN1 KCNK3 NPPB PDE5A
2	chronic thromboembolic pulmonary hypertension	34.3	BMPR2 EDN1 NPPB
3	pulmonary venoocclusive disease	33.3	ACVRL1 BMPR2 KCNK3
4	persistent fetal circulation syndrome	33.1	EDN1 EDNRA NOS3 PDE5A
5	heritable pulmonary arterial hypertension	32.9	ACVRL1 BMPR2 CAV1 KCNK3 SMAD9
6	heart disease	31.2	BMPR2 EDN1 EDNRA NOS3 NPPB PDE5A
7	connective tissue disease	31.1	ACVRL1 BMPR2 EDN1 EDNRA
8	vascular disease	30.8	ACVRL1 BMPR2 EDN1 MIR21 NOS3
9	pulmonary edema	30.7	EDN1 NOS3 NPPB
10	sleep apnea	30.7	EDN1 NOS3 NPPB
11	congestive heart failure	30.5	EDN1 MIR21 NPPB
12	hepatopulmonary syndrome	30.5	ACVRL1 BMPR2 EDN1 NOS3
13	portal hypertension	30.5	BMPR2 EDN1 EDNRA NOS3
14	chronic mountain sickness	30.4	EDN1 NOS3 NPPB
15	arteries, anomalies of	30.1	ACVRL1 BMPR2 EDN1 NOS3 NPPB
16	coronary artery anomaly	30.1	EDN1 NOS3 NPPB
17	central sleep apnea	30.1	NOS3 NPPB
18	ischemic optic neuropathy	30.0	EDN1 NOS3 PDE5A
19	chronic pulmonary heart disease	30.0	ACVRL1 BMPR2 EDN1 SLC6A4 SMAD9
20	myocardial infarction	29.9	EDN1 MIR21 NOS3 NPPB PDE5A
21	angina pectoris	29.8	EDN1 NOS3 NPPB
22	impotence	29.8	EDN1 NOS3 PDE5A
23	nonarteritic anterior ischemic optic neuropathy	29.8	EDN1 NOS3 PDE5A
24	hypertension, essential	29.7	EDN1 EDNRA NOS3 NPPB
25	hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome	12.6
26	pulmonary hypertension, primary, 4	12.5
27	pulmonary hypertension, primary, 2	12.4
28	pulmonary hypertension, primary, 3	12.4
29	pulmonary hypertension, neonatal	12.4
30	pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis	12.4
31	vater-like defects with pulmonary hypertension, laryngeal webs, and growth deficiency	12.1
32	pulmonary hypertension, primary, autosomal recessive	12.1
33	alveolar capillary dysplasia with misalignment of pulmonary veins	11.8
34	pulmonary edema of mountaineers	11.7
35	eisenmenger syndrome	11.7
36	lymphedema and cerebral arteriovenous anomaly	11.6
37	alveolar capillary dysplasia	11.6
38	pulmonary fibrosis, idiopathic	11.5
39	hypoxia	11.5
40	pulmonary venoocclusive disease 2, autosomal recessive	11.5
41	cantu syndrome	11.5
42	diaphragmatic hernia, congenital	11.4
43	patent ductus arteriosus 1	11.4
44	pulmonary venoocclusive disease 1, autosomal dominant	11.4
45	pulmonary vein stenosis	11.3
46	pulmonary valve insufficiency	11.3
47	unilateral absence of a pulmonary artery	11.3
48	adams-oliver syndrome 1	11.3
49	dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema	11.3
50	adams-oliver syndrome	11.3

Graphical network of the top 20 diseases related to Pulmonary Hypertension:

Sources

Symptoms & Phenotypes for Pulmonary Hypertension

UMLS symptoms related to Pulmonary Hypertension:

dyspnea, angina pectoris, edema, hemoptysis, chest pain, snoring, coughing

MGI Mouse Phenotypes related to Pulmonary Hypertension:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.97	ACVRL1 BMPR2 CAV1 EDN1 EDNRA KCNK3
2	muscle	MP:0005369	9.86	ACVRL1 BMPR2 CAV1 EDN1 EDNRA NOS3
3	nervous system	MP:0003631	9.85	ACVRL1 BMPR1B BMPR2 CAV1 EDN1 EDNRA
4	normal	MP:0002873	9.61	ACVRL1 BMPR1B BMPR2 EDN1 EDNRA KCNK3
5	respiratory system	MP:0005388	9.17	ACVRL1 BMPR2 CAV1 EDNRA KCNK3 NOS3

Sources

Drugs & Therapeutics for Pulmonary Hypertension

PubMedHealth treatment related to Pulmonary Hypertension: ⁶³

Pulmonary hypertension (PH) has no cure. However, treatment may help relieve symptoms and slow the progress of the disease.PH is treated with medicines, procedures, and other therapies. Treatment will depend on what type of PH you have and its severity. (For more information, go to "Types of Pulmonary Hypertension.")

FDA approved drugs:

(show all 7)

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Adcirca ¹⁸	TADALAFIL	Eli Lilly	May 2009
FDA Label: Adcirca Disease/s that Drug Treats:pulmonary arterial hypertension Indications and Usage: ¹⁸ ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II - III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). (1.1) DrugBank Targets: ¹⁶ cGMP-specific 3',5'-cyclic phosphodiesterase\|Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A Mechanism of Action: ¹⁸ Target: phosphodiesterase type 5 (PDE5) Action: oral inhibitor FDA: Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary arterial hypertension is associated with impaired release of nitric oxide by the vascular endothelium and consequent reduction of cGMP concentrations in the pulmonary vascular smooth muscle. PDE5 is the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 by tadalafil increases the concentrations of cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. Studies in vitro have demonstrated that tadalafil is a selective inhibitor of PDE5. PDE5 is found in pulmonary vascular smooth muscle, visceral smooth muscle, corpus cavernosum, skeletal muscle, platelets, kidney, lung, cerebellum, and pancreas.In vitro studies have shown that the effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. These studies have shown that tadalafil is >10,000-fold more potent for PDE5 than for PDE1, PDE2, PDE4, and PDE7 enzymes, which are found in the heart, brain, blood vessels, liver, leukocytes, skeletal muscle, and other organs. Tadalafil is >10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. Additionally, tadalafil is 700-fold more potent for PDE5 than for PDE6, which is found in the retina and is responsible for phototransduction. Tadalafil is >9,000-fold more potent for PDE5 than for PDE8, PDE9, and PDE10. Tadalafil is 14-fold more potent for PDE5 than for PDE11A1 and 40-fold more potent for PDE5 than for PDE11A4, two of the four known forms of PDE11. PDE11 is an enzyme found in human prostate, testes, skeletal muscle and in other tissues. In vitro, tadalafil inhibits human recombinant PDE11A1 and, to a lesser degree, PDE11A4 activities at concentrations within the therapeutic range. The physiological role and clinical consequence of PDE11 inhibition in humans have not been defined.
2	Adempas ¹⁸	RIOCIGUAT	Bayer Healthcare Pharmaceuticals	October 2013
FDA Label: Adempas Disease/s that Drug Treats:Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension Indications and Usage: ¹⁸ Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: * Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. (1.1) * Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. (1.2) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: soluble guanylate cyclase (sGC) Action: stimulator FDA: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation.Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat stimulates the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation. The active metabolite (M1) of riociguat is 1/3 to 1/10 as potent as riociguat.
3	Letairis ¹⁸	AMBRISENTAN	Gilead	June 2007
FDA Label: Letairis Disease/s that Drug Treats:pulmonary arterial hypertension Indications and Usage: ¹⁸ Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): * To improve exercise ability and delay clinical worsening. * In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II-III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) (1). DrugBank Targets: ¹⁶ Endothelin-1 receptor\|Endothelin B receptor Mechanism of Action: ¹⁸ Target: endothelin receptor Action: type-A selective antagonist FDA: Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of patients with PAH, primarily in the endothelium of pulmonary arteries. These findings suggest that ET-1 may play a critical role in the pathogenesis and progression of PAH. Ambrisentan is a high-affinity (Ki=0.011 nM) ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.
4	Opsumit ¹⁸	MACITENTAN	Actelion Pharmaceuticals	October 2013
FDA Label: Opsumit Disease/s that Drug Treats:pulmonary arterial hypertension Indications and Usage: ¹⁸ OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH (1.1). DrugBank Targets: ¹⁶ Endothelin-1 receptor\|Endothelin B receptor Mechanism of Action: ¹⁸ Target: Endothelin Receptor Action: antagonist FDA: Endothelin (ET)-1 and its receptors (ETA and ETB) mediate a variety of deleterious effects, such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular hypertrophy and in organ damage. Macitentan is an endothelin receptor antagonist that prevents the binding of ET-1 to both ETA and ETB receptors. Macitentan displays high affinity and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells. One of the metabolites of macitentan is also pharmacologically active at the ET receptors and is estimated to be about 20% as potent as the parent drug in vitro.
5	Remodulin ¹⁸	TREPROSTINIL	United Therapeutics	May 2002
FDA Label: Remodulin Disease/s that Drug Treats:pulmonary arterial hypertension Indications and Usage: ¹⁸ Remodulin is a prostacyclin vasodilator indicated for: * Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) (1.1) * Patients who require transition from FlolanÂ®, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2) DrugBank Targets: ¹⁶ Prostacyclin receptor\|Peroxisome proliferator-activated receptor delta\|P2Y purinoceptor 12 Mechanism of Action: ¹⁸ Target: pulmonary and systemic arterial vascular beds\|platelet aggregation Action: direct vasodilation\|inhibition FDA: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
6	Tracleer ¹⁸	BOSENTAN	Actelion	November 2001
FDA Label: Tracleer Disease/s that Drug Treats:Pulmonary arterial hypertension Indications and Usage: ¹⁸ Tracleer is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) (1.1). Considerations for use: Consider whether benefits offset the risk of hepatotoxicity in WHO Class II patients. Early hepatotoxicity may preclude future use as disease progresses (1.1). DrugBank Targets: ¹⁶ Endothelin B receptor\|Endothelin-1 receptor Mechanism of Action: ¹⁸ Target: endothelin receptor types ETA and ETB Action: specific and competitive antagonist FDA: Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. Bosentan has a slightly higher affinity for ETA receptors than for ETB receptors. The clinical impact of dual endothelin blockage is unknown. Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease.
7	Tyvaso ¹⁸	TREPROSTINIL	United Therapeutics	July 2009
FDA Label: Tyvaso Disease/s that Drug Treats:pulmonary arterial hypertension Indications and Usage: ¹⁸ Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). (1) DrugBank Targets: ¹⁶ Prostacyclin receptor\|Peroxisome proliferator-activated receptor delta\|P2Y purinoceptor 12 Mechanism of Action: ¹⁸ Target: - Action: - FDA: Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

Drugs for Pulmonary Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 435)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bosentan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

147536-97-8

104865

Iloprost

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

78919-13-8

6443959

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

94-09-7, 1994-09-7

2337

tannic acid

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

Spironolactone

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

52-01-7, 1952-01-7

5833

Iron

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

7439-89-6

23925

Tadalafil

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

171596-29-5

110635

Epoprostenol

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

61849-14-7, 35121-78-9

5280427 5282411

Treprostinil

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

81846-19-7

54786 6918140

Warfarin

Approved

Phase 4,Phase 2

81-81-2

6691 54678486

Heparin

Approved, Investigational

Phase 4,Phase 3

9005-49-6

772 46507594

Nitric Oxide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

10102-43-9

145068

Ambrisentan

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

177036-94-1

6918493

Macitentan

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

441798-33-0

Lidocaine

Approved, Vet_approved

Phase 4,Phase 1,Not Applicable

137-58-6

3676

Ranolazine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

142387-99-3, 95635-55-5

56959

Dalteparin

Approved

Phase 4,Phase 3

9005-49-6

Isoflurane

Approved, Vet_approved

Phase 4

26675-46-7

3763

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Clevidipine

Approved, Investigational

Phase 4

167221-71-8

Zinc

Approved, Investigational

Phase 4,Not Applicable

7440-66-6

Magnesium oxide

Approved

Phase 4

1309-48-4

14792

Silver sulfadiazine

Approved, Vet_approved

Phase 4

22199-08-2

441244

Acetazolamide

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

59-66-5

1986

Poractant alfa

Approved

Phase 4,Phase 3

129069-19-8

Selexipag

Approved

Phase 4,Phase 3,Phase 2

475086-01-2

Ibuprofen

Approved

Phase 4,Phase 3,Not Applicable

15687-27-1

3672

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Nebivolol

Approved, Investigational

Phase 4

99200-09-6, 152520-56-4, 118457-14-0

71301

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Morphine

Approved, Investigational

Phase 4,Phase 2

57-27-2

5288826

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

77-92-9

311

Serine

Approved, Nutraceutical

Phase 4,Phase 1

56-45-1

5951

Tezosentan

Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

180384-57-0

Beraprost

Investigational

Phase 4,Phase 3,Phase 2

88430-50-6

Lactitol

Investigational

Phase 4

585-86-4

3871

Vasodilator Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Sildenafil Citrate

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

171599-83-0

Endothelin Receptor Antagonists

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Citrate

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Phosphodiesterase 5 Inhibitors

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antihypertensive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Phosphodiesterase Inhibitors

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Platelet Aggregation Inhibitors

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Diuretics, Potassium Sparing

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

diuretics

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Mineralocorticoids

Phase 4,Phase 2,Phase 1,Not Applicable

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1155)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia	Unknown status	NCT01449253	Phase 4	Sildenafil;Bosentan
2	Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)	Unknown status	NCT01116063	Phase 4	Inhaled iloprost
3	Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study	Unknown status	NCT00637065	Phase 4	Bosentan;Placebo
4	Riociguat for Sarcoidosis Associated Pulmonary Hypertension	Unknown status	NCT02625558	Phase 4	Riociguat;Placebo
5	Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.	Unknown status	NCT02963597	Phase 4
6	Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension	Unknown status	NCT01468571	Phase 4	Spironolactone;Placebo
7	Iron Deficiency In Pulmonary Hypertension	Unknown status	NCT01288651	Phase 4	Ferricarboxymaltose
8	Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost	Unknown status	NCT01649739	Phase 4	Levitra
9	Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.	Unknown status	NCT00705588	Phase 4	Tadalafil;Vardenafil
10	Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism	Unknown status	NCT02029456	Phase 4	25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
11	Hemodynamic Response After Six Months of Sildenafil	Unknown status	NCT00483626	Phase 4	oral sildenafil
12	Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure	Unknown status	NCT00793338	Phase 4	Sildenafil
13	Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain	Unknown status	NCT01615627	Phase 4	HypotonicTreprostinil Solution;Eutonic Treprostinil Solution
14	Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy	Unknown status	NCT02979561	Phase 4	Dabigatran Etexilate;Warfarin
15	Targeting the Right Ventricle in Pulmonary Hypertension	Completed	NCT01839110	Phase 4	Ranolazine;Placebo
16	PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension	Completed	NCT02378649	Phase 4	Sildenafil;Placebo
17	Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction	Completed	NCT02133352	Phase 4	Ranolazine
18	VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension	Completed	NCT01889966	Phase 4	Sildenafil
19	Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension	Completed	NCT01055405	Phase 4	Sildenafil
20	Natrecor for Pulmonary Hypertension in Lung Transplants	Completed	NCT00205426	Phase 4	Natrecor
21	Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan	Completed	NCT01051960	Phase 4	Ambrisentan
22	Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns	Completed	NCT01757782	Phase 4	Oral Sildenafil;Placebo (distilled water)
23	Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease	Completed	NCT00862043	Phase 4	Sildenafil Citrate;Placebo
24	Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism	Completed	NCT02132689	Phase 4	Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy)
25	Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension	Completed	NCT01330108	Phase 4	ambrisentan
26	Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD)	Completed	NCT00491803	Phase 4	Sildenafil;Sildenafil
27	Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension	Completed	NCT00403650	Phase 4	Iloprost
28	Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)	Completed	NCT02191137	Phase 4	Riociguat (Adempas, BAY63-2521)
29	Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension	Completed	NCT00004754	Phase 4	epoprostenol
30	Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children	Completed	NCT03431649	Phase 4	Beraprost Sodium;Sildenafil Citrate
31	Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.	Completed	NCT01800292	Phase 4	sildenafil
32	Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement	Completed	NCT01717209	Phase 4	Nitric Oxide;Prostacyclin
33	Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin	Completed	NCT00373360	Phase 4	treprostinil sodium
34	Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance	Completed	NCT01212523	Phase 4	propofol and isoflurane
35	Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).	Completed	NCT00878878	Phase 4	Optison (Perflutren Protein-Type A Microspheres Injectable Suspension);Dextrose
36	A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension	Completed	NCT00058929	Phase 4	treprostinil sodium
37	Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude	Completed	NCT02024386	Phase 4	Riociguat
38	BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology	Completed	NCT00367770	Phase 4	Tracleer®
39	Effects of Viagra on Heart Function in Patients With Heart Failure	Completed	NCT00781508	Phase 4	sildenafil
40	Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed	Completed	NCT01121458	Phase 4	Clevidipine
41	Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication	Completed	NCT01268553	Phase 4	Treprostinil
42	Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis	Completed	NCT01060020	Phase 4	Sildenafil
43	Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)	Completed	NCT02847260	Phase 4	Remodulin
44	Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.	Completed	NCT02595684	Phase 4	Tadalafil;Placebo
45	Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients	Completed	NCT01996124	Phase 4	Indacaterol Fumarate;Placebo
46	Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)	Completed	NCT00303459	Phase 4	bosentan;placebo
47	Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects	Completed	NCT00741819	Phase 4	Inhaled treprostinil
48	Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)	Completed	NCT00617305	Phase 4	Ambrisentan;Placebo;Sildenafil;Tadalafil
49	A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis	Completed	NCT01042158	Phase 4	tadalafil and ambrisentan upfront combination therapy
50	Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension	Completed	NCT00323297	Phase 4	Bosentan;Bosentan;Sildenafil Citrate

Search NIH Clinical Center for Pulmonary Hypertension

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

alprostadil

bosentan

epoprostenol

epoprostenol sodium

hydralazine

hydralazine hydrochloride

nitroglycerin

treprostinil

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Pulmonary Hypertension cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Pulmonary Hypertension:

	Endothelial progenitor cells for pulmonary hypertension
	Endothelial progenitors for treatment of idiopathic pulmonary arterial hypertension

Embryonic/Adult Cultured Cells Related to Pulmonary Hypertension:

	eNOS-transfected endothelial progenitor cells PMIDs: 21653527 20117135
	eNOS-transfected endothelial progenitor cells PMIDs: 21653527 20117135
	Peripheral blood-derived endothelial progenitor cells PMIDs: 17418297

Cochrane evidence based reviews: hypertension, pulmonary

Sources

Genetic Tests for Pulmonary Hypertension

Genetic tests related to Pulmonary Hypertension:

#	Genetic test	Affiliating Genes
1	Primary Pulmonary Hypertension ²⁹	BMPR2

Sources

Anatomical Context for Pulmonary Hypertension

MalaCards organs/tissues related to Pulmonary Hypertension:

⁴¹

Heart, Lung, Endothelial, Testes, Smooth Muscle, Liver, Brain

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pulmonary Hypertension:

#	Tissue Anatomical CompartmentCell	Relevance
1	Lung Pulmonary Capillary Plexus	Affected by disease

Sources

Publications for Pulmonary Hypertension

Articles related to Pulmonary Hypertension:

(show top 50) (show all 5480)

#	Title	Authors	Year
1	Right ventricular function in infants with bronchopulmonary dysplasia and pulmonary hypertension: a pilot study. ( 30419798 )	Blanca AJ...Koopman LP	2019
2	Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ( 30011997 )	Ivarsson B...Kjellstr?m B	2019
3	Validation of a claims-based algorithm to identify patients with chronic thromboembolic pulmonary hypertension using electronic health record data. ( 30419792 )	Teal S...Fabian J	2019
4	Hemodynamics of the diastolic pressure gradients in acute heart failure: implications for the diagnosis of pre-capillary pulmonary hypertension in left heart disease. ( 30419797 )	Aronson D...Burger AJ	2019
5	MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension. ( 30551428 )	Li Y...Shi B	2019
6	Stabilization of p22phox by Hypoxia Promotes Pulmonary Hypertension. ( 30044141 )	Zhang Z...G?rlach A	2019
7	Tricuspid annular plane systolic excursion (TAPSE) in pediatric pulmonary hypertension: Integrating right ventricular ejection efficiency (RVEe) into advanced multi-parametric imaging. ( 30454722 )	Koestenberger M...European Pediatric Pulmonary Vascular Disease Network	2019
8	Target oxygen saturation and development of pulmonary hypertension and increased pulmonary vascular resistance in preterm infants. ( 30461218 )	Lalibert? C...Katz SL	2019
9	Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension. ( 30485728 )	Bacha NC...Smadja DM	2019
10	AOS ameliorates monocrotaline-induced pulmonary hypertension by restraining the activation of P-selectin/p38MAPK/NF-κB pathway in rats. ( 30551382 )	Hu Y...Mao Y	2019
11	Genipin attenuates hyperoxia-induced lung injury and pulmonary hypertension via targeting glycogen synthase kinase-3 β in neonatal rats. ( 30196116 )	Li J...Liu A	2019
12	Anesthetic management of an infant with Jeune syndrome and severe pulmonary hypertension for tracheostomy. ( 30218885 )	Salik I...Barst S	2019
13	Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the NG, NG-dimethyl-L-arginine metabolism pathways in rats. ( 30419238 )	Dai G...Yang H	2019
14	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. ( 30419796 )	D'Alto M...Golino P	2019
15	Proximal pulmonary arterial wall disease in patients with persistent pulmonary hypertension after successful left-sided valve replacement according to the hemodynamic phenotype. ( 30430894 )	Domingo E...Roman A	2019
16	Pulmonary Hypertension in Women. ( 30449376 )	Franco V...McLaughlin VV	2019
17	Pulmonary hypertension in an adolescent with end-stage-renal disease-a diagnostic challenge: Questions. ( 29532234 )	Hogan J...Legendre A	2019
18	Pulmonary hypertension in an adolescent with end-stage-renal disease-a diagnostic challenge: Answers. ( 29532236 )	Hogan J...Legendre A	2019
19	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Observational Study in a Referral Unit. ( 29857972 )	VelA!zquez M....Escribano P.	2018
20	Sequential Hybrid Therapy With Pulmonary Endarterectomy and Additional Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. ( 29929993 )	Yanaka K....Hirata K.I.	2018
21	Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia. ( 29773690 )	King C.S....Nathan S.D.	2018
22	Impact of Balloon Pulmonary Angioplasty on Hemodynamics and Clinical Outcomes in Patients with Chronic Thromboembolic Pulmonary Hypertension: the Initial Korean Experience. ( 29318791 )	Kwon W....Kim D.K.	2018
23	Approach to Pulmonary Hypertension: From CT to Clinical Diagnosis. ( 29432063 )	Aluja Jaramillo F....Bhalla S.	2018
24	Balloon Pulmonary Angioplasty Relieves Hemodynamic Stress towards Untreated-Side Pulmonary Vasculature and Ameliorates Its Resistance in Patients with Chronic Thromboembolic Pulmonary Hypertension. ( 29360065 )	Hosokawa K....Tsutsui H.	2018
25	Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. ( 29909420 )	Smukowska-Gorynia A....Mularek-Kubzdela T.	2018
26	Vascular endothelial growth factor and pulmonary hypertension in children with beta thalassemia major. ( 29859904 )	Alkholy U.M....Zaki A.	2018
27	Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. ( 29966637 )	Tseng S....Saggar R.	2018
28	Epidemiology and risk factors for chronic thromboembolic pulmonary hypertension. ( 29338883 )	Fernandes T....Fedullo P.	2018
29	Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. ( 29791520 )	Gavilanes-Oleas F.A....Souza R.	2018
30	Bosentan Therapy for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Systemic Review and Meta-Analysis. ( 29393580 )	Chen X....Wang C.	2018
31	Pulmonary Hypertension in Aortic and Mitral Valve Disease. ( 29876357 )	Maeder M.T....Rickli H.	2018
32	Severe Compression of the Left Main Coronary Artery in a Patient with Chronic Thromboembolic Pulmonary Hypertension. ( 29321385 )	Sugiyama K....Ogino H.	2018
33	Screening for pulmonary hypertension in interstitial lung disease: Many reasons to ECHO! ( 29415370 )	Prasad J.D.	2018
34	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. ( 29730328 )	Taniguchi Y....Simonneau G.	2018
35	Macitentan in pulmonary hypertension due to left ventricular dysfunction. ( 29437943 )	VachiAcry J.L....Rubin L.J.	2018
36	MRI-derived Regional Biventricular Function in Patients with Chronic Thromboembolic Pulmonary Hypertension Before and After Pulmonary Endarterectomy. ( 29730148 )	Maschke S.K....Vogel-Claussen J.	2018
37	Perioperative events in children with pulmonary hypertension undergoing non-cardiac procedures. ( 28971729 )	Bernier M.L....Unegbu C.C.	2018
38	Biomarkers in Pulmonary Hypertension. ( 29966636 )	Marra A.M....Cittadini A.	2018
39	Pulmonary Hypertension in Glycogen Storage Disease Type II. ( 29786057 )	Li H.P....Wang C.	2018
40	Impact of histologic chorioamnionitis on pulmonary hypertension and respiratory outcomes in preterm infants. ( 29480140 )	Yum S.K....Sung I.K.	2018
41	Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. ( 29439019 )	Caravita S....VachiAcry J.L.	2018
42	Usefulness of scoring right ventricular function for assessment of prognostic factors in patients with chronic thromboembolic pulmonary hypertension. ( 29704099 )	Kamimura Y....Kondo T.	2018
43	Twist1 in Hypoxia-induced Pulmonary Hypertension through Transforming Growth Factor-I^-Smad Signaling. ( 28915063 )	Mammoto T....Mammoto A.	2018
44	Will we be singing a different tune on combined post- and pre-capillary pulmonary hypertension? ( 29437950 )	Hsu S....Tedford R.J.	2018
45	Surgery for partial atrioventricular septal defect with pulmonary hypertension in an adult dog. ( 29877312 )	Goya S....Fujioka T.	2018
46	Severe Pulmonary Hypertension Due to Adult-Onset Still's Disease. ( 29468168 )	Sinha A....Chawla K.	2018
47	Lethal persistent pulmonary hypertension of the newborn in Bohring-Opitz syndrome. ( 29681105 )	Kibe M....Ikeda T.	2018
48	Persistent Pulmonary Hypertension and Histologic Chorioamnionitis in Preterm Infants: Controlled Study. ( 29453682 )	Katz N....Kohelet D.	2018
49	NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. ( 29977013 )	Dasgupta S....Jain S.K.	2018
50	Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study. ( 29326818 )	Ivarsson B....KjellstrAPm B.	2018

Sources

Genes for Pulmonary Hypertension

Genes related to Pulmonary Hypertension (3 elite genes):

(show top 50) (show all 52)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIR759	MicroRNA 759	RNA Gene	360.72	Causal ⁴⁷ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	20677013
2	MIR20A	MicroRNA 20a	RNA Gene	356.31	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19390056
3	BMPR2	Bone Morphogenetic Protein Receptor Type 2	Protein Coding	189.65	Genetic Tests ²⁹ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)	12571257 11940546 19390056 (more) 15286002 16840720 12384956 15466636 17065373 20095988 16717148 18356561 17641158 19844076 17287300 11753283 16361357 12358323 11484689 15170098 18283205 15615096 18552156 18202349 11015450 19786120
3	BMPR2::MIR20A ⁴⁷	MIR20A Macro RNA (hsa-miR-20a) targets BMPR2
4	TNXA	Tenascin XA (Pseudogene)	Pseudogene	150	Experimental evidence: Regulation ³⁹	25522749
5	MIR21	MicroRNA 21	RNA Gene	56.31	Unspecified ⁴⁷ GeneCards inferred via : Publications (show sections)	20110569
6	CAV1	Caveolin 1	Protein Coding	51.06	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Publications Variants (show sections)	19572028 18226570 20382348 (more) 18296499 19487814
7	MIR451A	MicroRNA 451a	RNA Gene	50	Unspecified ⁴⁷	20110569
8	MIR22	MicroRNA 22	RNA Gene	50	Unspecified ⁴⁷	20110569
9	ACVRL1	Activin A Receptor Like Type 1	Protein Coding	49.91	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Variants (show sections)	11484689 16941203 18202349 (more) 14684682 17641482
10	KCNK3	Potassium Two Pore Domain Channel Subfamily K Member 3	Protein Coding	47.47	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
11	CPS1	Carbamoyl-Phosphate Synthase 1	Protein Coding	46.02	GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
12	EDN1	Endothelin 1	Protein Coding	43.37	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8594905 16864942 10625089 (more) 19632577 8497283 8855433 7705179 11887493 9628300 11317642 11902294 9054770 14569522 12788984 7653485 12391278 8099638 9539476 7805238 9861298 7788905 10768278 9918748 1994793 20481052 10585047 9535437 7584571 11121812 11078436 9311502 9108859 8256914 8342919 7495344 16327149 9918974 11480254 10364736 9741571 9059544 8865978 8320603 1735147 17641401 15938827 15751522 12423564 15470654 10976782 10369113 9257140 9275630 11326879 10690304 18297323 18279809 12970246 10503184 8361190 16982943 9736439 9595502 7836103 8155168 8247067 8176102 18682983 18567602 17897273 16219361 15576275 12934401 12628956 10099694 10598486 9918744 9853916 9794709 15753756 12193107 11725953 11447303 10794331 10678379 10543508 7794041 20040765 19544975 18814097 17583185 16919004 14526432 12407540 12224443 9730795 9104988 9066378 7800957
13	SARS2	Seryl-TRNA Synthetase 2, Mitochondrial	Protein Coding	41.1	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
14	SMAD9	SMAD Family Member 9	Protein Coding	39.89	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Disorders Variants (show sections)
15	PDE5A	Phosphodiesterase 5A	Protein Coding	39.66	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17305584 19416631 15907910 (more) 15817798 17275845 16716091 17965319 20225909 16808546 18040025 16755146 18673225 19377497 16387564 20030481 17305582 15115189 12466227 18728748 18346713 17691956 16735511 16901064 19659904 16387567 19181291 16095162 19544683 18953278 18367027 18536732 15977967 16291042
16	BMPR1B	Bone Morphogenetic Protein Receptor Type 1B	Protein Coding	38.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries Variants (show sections)
17	NOS3	Nitric Oxide Synthase 3	Protein Coding	38.02	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12904860 9950892 9727710 (more) 11371423 7540722 9815072 18790993 10197682 11509453 15531748 12547729 11045975 9771486 11411117 10373757 20382348 19572028 18953956 14966819 17715635 12720199 11343992 19487814 9395516 14766668 16520964 14682408 7477212 17827253 17878410 15498534 11770418
18	EDNRA	Endothelin Receptor Type A	Protein Coding	36.75	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7705179 9918974 11480254 (more) 11078412 16327149 9252542 16356485 12815302 7584571
19	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	36.05	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12024106 15927991 15302679 (more) 16002749 14530202 16878724 16373820 19556740 16339917 16615363 10841509 19679640 15142967 16009349
20	NPPB	Natriuretic Peptide B	Protein Coding	35.96	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16415273 17228802 20481052 (more) 15087298 19098338 9426041 19247590 16822585 18793807 18599134 17975752 19459423 9704693 15520111 20054445 17643631 20519078 10952954 15486400 20085871 17296640 16242811 16183564 8736661 19468826 15175210 8703666 18229565 15805406 16148485 12828576 16478861 19996941 15965809 18158473 15302622 19626418 11020459 17786380 17345160 9277439 11255693
21	SMAD4	SMAD Family Member 4	Protein Coding	35.51	GeneCards inferred via : Disorders Publications Variants (show sections)
22	ADM	Adrenomedullin	Protein Coding	35.36	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11802959 9857104 11083748 (more) 16787197 15501535 12630825 12750441 14691636 14526432 9725392 9185657 12835224 19337232 17902148 15047974 15459126 10352550 15506383 17251392 11115419 11083724 12947501 15886352 9404257 12147239 15997387
23	EDNRB	Endothelin Receptor Type B	Protein Coding	34.81	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18567602 11000137
24	ENG	Endoglin	Protein Coding	33.85	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications Variants (show sections)
25	NPPA	Natriuretic Peptide A	Protein Coding	32.57	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7705179 15911074 8393399 (more) 9277439 8853287 9628300 11583893 10768278 7838802 8202879 7758554 9704693 8537207 12828576 9805912 9201062 9426041 8266977 1319811 16822585 10553928 8703666 8540445 20376887 11020459 1839131 9404133 11353932 1642247
26	EIF2AK4	Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4	Protein Coding	32.22	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
27	KCNA5	Potassium Voltage-Gated Channel Subfamily A Member 5	Protein Coding	21.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
28	ANGPT1	Angiopoietin 1	Protein Coding	21.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11436038 15678035 14759414 (more) 12571257 15466636 15615096 14512515 12750304 17570156
29	THBD	Thrombomodulin	Protein Coding	20.48	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10666169 14555559 8757355 (more) 10690304 8694622 9622208
30	VIP	Vasoactive Intestinal Peptide	Protein Coding	20.27	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19581838 16247516 2187492 (more) 16341283 18328650 18978135 16607490 14985177 19121410
31	PTGIR	Prostaglandin I2 Receptor	Protein Coding	19.87	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
32	TBX4	T-Box 4	Protein Coding	19.71	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
33	PTGIS	Prostaglandin I2 Synthase	Protein Coding	19.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10359560 11034952 15541968 (more) 15049720 15182267 12019369 10351941
34	DYNLT1	Dynein Light Chain Tctex-Type 1	Protein Coding	18.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Proteins (show sections)
35	ACE	Angiotensin I Converting Enzyme	Protein Coding	18.93	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
36	BMP4	Bone Morphogenetic Protein 4	Protein Coding	18.41	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16373851 18539760
37	UTS2	Urotensin 2	Protein Coding	18.35	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16631735 16324296 18000598 (more) 12381671 19199921 20421634 14615276
38	NOS2	Nitric Oxide Synthase 2	Protein Coding	18.34	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	11371423 12904860 16169754 (more) 9486205 15942164 7584571 16456243 10666111 16050125 19912632 19273179 17965319 8947958 16553284 15364894 9612300 9815072 16553285 11509453
39	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	18.15	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16373853 17045016 11590837
40	HTR2B	5-Hydroxytryptamine Receptor 2B	Protein Coding	18.05	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
41	BMP2	Bone Morphogenetic Protein 2	Protein Coding	17.63	DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18070548
42	NOX4	NADPH Oxidase 4	Protein Coding	17.28	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17585072
43	VWF	Von Willebrand Factor	Protein Coding	17.27	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
44	RHOA	Ras Homolog Family Member A	Protein Coding	17.01	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16428270 19416631 15109211 (more) 19299501
45	PPH2	Primary Pulmonary Hypertension 2	Genetic Locus	16.61	GeneCards inferred via : Publications Gene name (show sections)
46	SMAD1	SMAD Family Member 1	Protein Coding	16.51	GeneCards inferred via : Disorders Variants (show sections)
47	TPH1	Tryptophan Hydroxylase 1	Protein Coding	16.11	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17130306 18176501
48	PLAT	Plasminogen Activator, Tissue Type	Protein Coding	16.02	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
49	NFU1	NFU1 Iron-Sulfur Cluster Scaffold	Protein Coding	16	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Disorders (show sections)
50	REN	Renin	Protein Coding	15.92	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Pulmonary Hypertension

Sources

Expression for Pulmonary Hypertension

Search GEO for disease gene expression data for Pulmonary Hypertension.

Sources

Pathways for Pulmonary Hypertension

Pathways related to Pulmonary Hypertension according to KEGG:

³⁷

#	Name	Kegg Source Accession
1	TGF-beta signaling pathway	hsa04350

Pathways related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	MicroRNAs in cancer ³⁷	12.27	BMPR2 MIR20A MIR21 MIR451A
2	DREAM Repression and Dynorphin Expression ⁶⁴ Show member pathways BMP Pathway ⁶⁴ Caspase Cascade ⁶⁴ Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels ⁶⁶ nNOS Signaling in Skeletal Muscle ⁶⁴ TOB in Osteoblast Signaling ⁶⁴	12.24	ACVRL1 BMPR1B BMPR2 SMAD9
3	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.2	BMPR1B BMPR2 NPPB SMAD9
4	Fluid shear stress and atherosclerosis ³⁷	11.7	BMPR1B BMPR2 CAV1 EDN1 NOS3
5	TGF-beta signaling pathway (KEGG) ³⁷	11.5	BMPR1B BMPR2 SMAD9
6	Signaling by BMP ⁶⁶ Show member pathways BMP receptor signaling ¹ Bone Morphogenic Protein (BMP) Signalling and Regulation ¹	11.36	BMPR1B BMPR2 SMAD9
7	Endothelin Pathways ¹	10.96	EDN1 EDNRA NOS3
8	ALK1 signaling events ¹ Show member pathways ALK1 pathway ¹	10.69	ACVRL1 BMPR2 CAV1 SMAD9
9	NO-dependent CFTR activation (normal and CF) ²²	10.55	NOS3 PDE5A
10	ALK2 signaling events ¹	10.41	BMPR2 SMAD9
11	Cardiomyocyte Differentiation through BMP Receptors ⁶⁴	10.27	BMPR1B BMPR2 NPPB SMAD9

Sources

GO Terms for Pulmonary Hypertension

Cellular components related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	integral component of plasma membrane	GO:0005887	9.7	ACVRL1 BMPR1B BMPR2 CAV1 EDNRA KCNK3
2	extracellular space	GO:0005615	9.56	BMPR2 EDN1 KCNK3 MIR20A MIR21 MIR22
3	caveola	GO:0005901	8.8	BMPR2 CAV1 NOS3

Biological processes related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

(show top 50) (show all 52)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.97	ACVRL1 EDN1 MIR20A MIR21
2	in utero embryonic development	GO:0001701	9.93	ACVRL1 EDN1 EDNRA NOS3
3	negative regulation of cell growth	GO:0030308	9.88	ACVRL1 BMPR2 NPPB
4	positive regulation of angiogenesis	GO:0045766	9.87	ACVRL1 MIR20A MIR21 NOS3
5	response to hypoxia	GO:0001666	9.83	ACVRL1 CAV1 EDN1 EDNRA SLC6A4
6	pattern specification process	GO:0007389	9.82	ACVRL1 BMPR1B BMPR2
7	cellular response to transforming growth factor beta stimulus	GO:0071560	9.8	ACVRL1 CAV1 EDN1
8	positive regulation of osteoblast differentiation	GO:0045669	9.79	BMPR1B BMPR2 MIR21
9	positive regulation of endothelial cell migration	GO:0010595	9.76	BMPR2 EDN1 MIR21
10	positive regulation of vascular smooth muscle cell proliferation	GO:1904707	9.75	EDN1 MIR20A MIR21
11	transforming growth factor beta receptor signaling pathway	GO:0007179	9.72	ACVRL1 BMPR1B BMPR2 MIR21 SMAD9
12	membrane depolarization	GO:0051899	9.71	CAV1 EDN1
13	negative regulation of endothelial cell migration	GO:0010596	9.71	ACVRL1 MIR21
14	positive regulation of chondrocyte differentiation	GO:0032332	9.71	ACVRL1 BMPR1B
15	blood vessel remodeling	GO:0001974	9.71	ACVRL1 BMPR2 NOS3
16	negative regulation of endothelial cell proliferation	GO:0001937	9.71	ACVRL1 CAV1 MIR21 MIR22
17	cellular response to peptide hormone stimulus	GO:0071375	9.7	CAV1 EDN1
18	regulation of nitric-oxide synthase activity	GO:0050999	9.7	CAV1 NOS3
19	vasodilation	GO:0042311	9.7	CPS1 NOS3
20	positive regulation of endothelial cell differentiation	GO:0045603	9.69	ACVRL1 MIR21
21	activin receptor signaling pathway	GO:0032924	9.69	ACVRL1 BMPR2
22	chondrocyte development	GO:0002063	9.69	BMPR1B BMPR2
23	positive regulation of cardiac muscle hypertrophy	GO:0010613	9.69	EDN1 MIR21 PDE5A
24	endocardial cushion morphogenesis	GO:0003203	9.68	ACVRL1 NOS3
25	positive regulation of cartilage development	GO:0061036	9.68	BMPR1B BMPR2
26	positive regulation of renal sodium excretion	GO:0035815	9.68	EDN1 NPPB
27	positive regulation of urine volume	GO:0035810	9.68	EDN1 NPPB
28	proteoglycan biosynthetic process	GO:0030166	9.67	BMPR1B BMPR2
29	negative regulation of DNA biosynthetic process	GO:2000279	9.67	ACVRL1 BMPR2
30	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.67	MIR20A MIR21 MIR451A
31	cellular response to BMP stimulus	GO:0071773	9.67	ACVRL1 BMPR1B BMPR2 SMAD9
32	lymphangiogenesis	GO:0001946	9.66	ACVRL1 BMPR2
33	response to dexamethasone	GO:0071548	9.66	CPS1 EDN1
34	artery smooth muscle contraction	GO:0014824	9.65	EDN1 EDNRA
35	body fluid secretion	GO:0007589	9.65	EDN1 NPPB
36	negative regulation of smooth muscle cell apoptotic process	GO:0034392	9.65	EDN1 MIR21
37	transmembrane receptor protein serine/threonine kinase signaling pathway	GO:0007178	9.65	ACVRL1 BMPR1B BMPR2
38	BMP signaling pathway	GO:0030509	9.65	ACVRL1 BMPR1B BMPR2 MIR21 SMAD9
39	artery development	GO:0060840	9.64	ACVRL1 BMPR2
40	retina vasculature development in camera-type eye	GO:0061298	9.63	ACVRL1 BMPR2
41	regulation of blood vessel size	GO:0050880	9.63	EDN1 NOS3 NPPB
42	endothelial tube morphogenesis	GO:0061154	9.61	ACVRL1 MIR21
43	regulation of glucose transmembrane transport	GO:0010827	9.61	EDN1 EDNRA
44	lymphatic endothelial cell differentiation	GO:0060836	9.6	ACVRL1 BMPR2
45	regulation of systemic arterial blood pressure by endothelin	GO:0003100	9.59	EDN1 NOS3
46	endochondral bone morphogenesis	GO:0060350	9.56	BMPR1B BMPR2
47	venous blood vessel development	GO:0060841	9.55	ACVRL1 BMPR2
48	regulation of the force of heart contraction by chemical signal	GO:0003057	9.52	CAV1 NOS3
49	regulation of blood pressure	GO:0008217	9.35	ACVRL1 EDN1 EDNRA NOS3 NPPB
50	negative regulation of chondrocyte proliferation	GO:1902731	9.33	BMPR1B BMPR2 MIR21

Molecular functions related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	SMAD binding	GO:0046332	9.43	ACVRL1 BMPR1B BMPR2
2	nitric-oxide synthase binding	GO:0050998	9.4	CAV1 SLC6A4
3	BMP receptor activity	GO:0098821	9.37	ACVRL1 BMPR2
4	growth factor binding	GO:0019838	9.33	ACVRL1 BMPR1B BMPR2
5	transforming growth factor beta receptor activity, type I	GO:0005025	9.32	ACVRL1 BMPR1B
6	transforming growth factor beta-activated receptor activity	GO:0005024	9.13	ACVRL1 BMPR1B BMPR2
7	transmembrane receptor protein serine/threonine kinase activity	GO:0004675	8.8	ACVRL1 BMPR1B BMPR2

Sources

Sources for Pulmonary Hypertension

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Pulmonary Hypertension

Aliases & Classifications for Pulmonary Hypertension

MalaCards integrated aliases for Pulmonary Hypertension:

Classifications:

External Ids:

Summaries for Pulmonary Hypertension

Related Diseases for Pulmonary Hypertension

Diseases in the Pulmonary Hypertension family:

Diseases related to Pulmonary Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Pulmonary Hypertension:

Symptoms & Phenotypes for Pulmonary Hypertension

UMLS symptoms related to Pulmonary Hypertension:

MGI Mouse Phenotypes related to Pulmonary Hypertension:

Drugs & Therapeutics for Pulmonary Hypertension

PubMedHealth treatment related to Pulmonary Hypertension: 63

FDA approved drugs:

Drugs for Pulmonary Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

Cochrane evidence based reviews: hypertension, pulmonary

Genetic Tests for Pulmonary Hypertension

Genetic tests related to Pulmonary Hypertension:

Anatomical Context for Pulmonary Hypertension

MalaCards organs/tissues related to Pulmonary Hypertension:

Publications for Pulmonary Hypertension

Articles related to Pulmonary Hypertension:

Genes for Pulmonary Hypertension

Genes related to Pulmonary Hypertension (3 elite genes):

Variations for Pulmonary Hypertension

Expression for Pulmonary Hypertension

Pathways for Pulmonary Hypertension

Pathways related to Pulmonary Hypertension according to KEGG:

Pathways related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

GO Terms for Pulmonary Hypertension

Cellular components related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

Biological processes related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

Molecular functions related to Pulmonary Hypertension according to GeneCards Suite gene sharing:

Sources for Pulmonary Hypertension

PubMedHealth treatment related to Pulmonary Hypertension: ⁶³

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :